News

Merck KGaA to buy Springworks for $3.9 billion
Merck KGaA acquires SpringWorks Therapeutics for $3.9B to enhance its cancer drug portfolio, boosting revenue growth and ...
STAT11h
Merck KGaA to purchase SpringWorks Therapeutics in deal worth more than $3 billion
After months of discussion, Germany’s Merck KGaA said Monday it would buy SpringWorks Therapeutics for $47 a share in cash, a ...
EMBO Press9h
A novel model of glioblastoma recurrence to identify therapeutic vulnerabilities
Unrepresentative pre-clinical models contribute to poor translation of glioblastoma research. We present an ...